Contemporary treatment of systemic lupus erythematosus: an update for clinicians

Maame B Amissah-Arthur, Caroline Gordon

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


The prognosis for patients with systemic lupus erythematosus (SLE) has improved significantly, with 20-year survival now approximately 80% owing partly to effective treatment. SLE treatment has evolved from the use of conventional drugs such as hydroxychloroquine and corticosteroids, nonspecific immunosuppressants including mycophenolate mofetil, to targeting selective components of the immune cascade with a view to increased efficacy, tolerability and safety profile. These novel treatments include B-cell-depleting antibodies and fusion proteins that block the costimulatory pathways of B and T cells. A discussion of these pharmacological options and ongoing research forms the basis of this review.
Original languageEnglish
Pages (from-to)163-75
Number of pages13
JournalTherapeutic advances in chronic disease
Issue number4
Publication statusPublished - Jul 2010


Dive into the research topics of 'Contemporary treatment of systemic lupus erythematosus: an update for clinicians'. Together they form a unique fingerprint.

Cite this